Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Oct 15, 2014; 6(10): 403-406
Published online Oct 15, 2014. doi: 10.4251/wjgo.v6.i10.403
Published online Oct 15, 2014. doi: 10.4251/wjgo.v6.i10.403
Neoadjuvant therapy for esophageal cancer
Rachit D Shah, Anthony D Cassano, James P Neifeld, Department of Surgery, Virginia Commonwealth University School of Medicine, Richmond, VA 23298-0068, United States
Author contributions: All the authors contributed to this paper.
Correspondence to: Rachit D Shah, MD, Assistant Professor of Surgery, Virginia Commonwealth University School of Medicine, PO Box 980068, Richmond, VA 23298-0068, United States. rshah@mcvh-vcu.edu
Telephone: +1-804-8284641 Fax: +1-804-6280537
Received: May 19, 2014
Revised: July 2, 2014
Accepted: September 6, 2014
Published online: October 15, 2014
Processing time: 153 Days and 22.1 Hours
Revised: July 2, 2014
Accepted: September 6, 2014
Published online: October 15, 2014
Processing time: 153 Days and 22.1 Hours
Core Tip
Core tip: This review evaluates the current literature on the use of neoadjuvant chemotherapy with or without radiation therapy for the treatment of locally advanced esophageal cancer. Major randomized controlled trials and co-operative group studies have been evaluated. Response rates, survival, complete response and outcomes have been thoroughly reviewed.